These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15673935)

  • 1. Impaired glucose tolerance, impaired fasting glycaemia and cardiovascular risk.
    Sanusi H
    Acta Med Indones; 2004; 36(1):36-41. PubMed ID: 15673935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients.
    Amini M; Horri N; Zare M; Haghighi S; Hosseini SM; Aminorroaya A; Hovsepian S
    Ann Nutr Metab; 2010; 56(4):267-72. PubMed ID: 20413967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab).
    Barr EL; Zimmet PZ; Welborn TA; Jolley D; Magliano DJ; Dunstan DW; Cameron AJ; Dwyer T; Taylor HR; Tonkin AM; Wong TY; McNeil J; Shaw JE
    Circulation; 2007 Jul; 116(2):151-7. PubMed ID: 17576864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
    Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
    Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study.
    Janssen PG; Gorter KJ; Stolk RP; Rutten GE
    Prim Care Diabetes; 2007 Jun; 1(2):69-74. PubMed ID: 18632022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired fasting glucose vs. glucose intolerance in pre-menopausal women: distinct metabolic entities and cardiovascular disease risk?
    Piché ME; Després JP; Pascot A; Nadeau A; Tremblay A; Weisnagel SJ; Bergeron J; Lemieux S
    Diabet Med; 2004 Jul; 21(7):730-7. PubMed ID: 15209766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.
    Karasik A
    Ann Med; 2005; 37(4):250-8. PubMed ID: 16019723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose and cardiovascular risk.
    Fuchs M; Hoekstra JB; Mudde AH
    Neth J Med; 2002 Jun; 60(5):192-9. PubMed ID: 12365474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of impaired fasting glucose and impaired glucose tolerance on arterial stiffness in an older Chinese population: the Guangzhou Biobank Cohort Study-CVD.
    Xu L; Jiang CQ; Lam TH; Cheng KK; Yue XJ; Lin JM; Zhang WS; Thomas GN
    Metabolism; 2010 Mar; 59(3):367-72. PubMed ID: 19828159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes].
    Köhler C; Temelkova-Kurktschiev T; Schaper F; Fücker K; Hanefeld M
    Dtsch Med Wochenschr; 1999 Sep; 124(37):1057-61. PubMed ID: 10520305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III).
    Muntner P; He J; Chen J; Fonseca V; Whelton PK
    Ann Epidemiol; 2004 Oct; 14(9):686-95. PubMed ID: 15380800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of The World Health Organization (WHO) two-step strategy and OGTT for diabetes mellitus screening.
    Adam JM; Tarigan NP
    Acta Med Indones; 2004; 36(1):3-7. PubMed ID: 15931695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes in hemodialyzed patients when applying new diagnostic criteria.
    Elbert A; Schreier L; Galli C; Beresan H; Lopez G; Traversa M; Berg G
    J Ren Nutr; 2006 Oct; 16(4):300-3. PubMed ID: 17046613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contemporary prospects of prevention of type 2 diabetes mellitus].
    Zeman M; Zák A
    Cas Lek Cesk; 2005; 144(3):147-51. PubMed ID: 15887394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease.
    Heldgaard PE; Olivarius Nde F; Hindsberger C; Henriksen JE
    Diabet Med; 2004 Apr; 21(4):363-70. PubMed ID: 15049940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes screening after gestational diabetes mellitus: poor performance of fasting plasma glucose.
    Cypryk K; Czupryniak L; Wilczyński J; Lewiński A
    Acta Diabetol; 2004 Mar; 41(1):5-8. PubMed ID: 15057547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired glucose tolerance is not associated with lipid intolerance.
    Henkel E; Temelkova-Kurktschiev T; Koehler C; Pietzsch J; Leonhardt W; Hanefeld M
    Diabetes Nutr Metab; 2002 Apr; 15(2):84-90. PubMed ID: 12059096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.